Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11011645 | 0.90 | GABRA1 (0.41) | GABRA1GABRB2HTR1AADRA2CADRA2A | |
| SCHEMBL8680424 | 0.86 | GABRA1 (0.45) | GABRA1GABRB2HTR1AADRA2CADRA2A | |
| SCHEMBL8985122 | 0.85 | GABRA1 (0.50) | GABRA1GABRB2HTR1AADRA2CADRA2A | |
| SCHEMBL29763626 | 0.85 | GABRA1 (0.56) | GABRA1GABRB2HTR1AADRA2CADRA2A | |
| SCHEMBL173300 | 0.85 | GABRA1 (0.56) | GABRA1GABRB2HTR1AADRA2CADRA2A | |
| Phosphine SCHEMBL28908229 | 0.83 | GABRA1 (0.54) | GABRA1GABRB2HTR1AADRA2CADRA2A | |
| Benzene SCHEMBL28085432 | 0.83 | GABRA1 (0.54) | GABRA1GABRB2HTR1AADRA2CADRA2A | |
| SCHEMBL19437729 | 0.83 | GABRA1 (0.54) | GABRA1GABRB2HTR1AADRA2CADRA2A | |
| SCHEMBL10528834 | 0.83 | GABRA1 (0.54) | GABRA1GABRB2HTR1AADRA2CADRA2A | |
| SCHEMBL11765775 | 0.83 | GABRA1 (0.54) | GABRA1GABRB2HTR1AADRA2CADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260003210-A1 | DIFFRACTIVE CONTACT LENSES | ALCON INC (CH) | 2026-01-01 | — | — | US | claimed |
| US-12379611-B2 | Diffractive contact lenses | ALCON INC. (CH) | 2025-08-05 | — | — | US | claimed |
| EP-4356169-A1 | MULTIFOCAL DIFFRACTIVE SILICONE HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2024-04-24 | — | — | EP | claimed |
| CN-117280252-A | Multifocal diffractive silicone hydrogel contact lenses | 爱尔康公司 | 2023-12-22 | — | — | CN | claimed |
| US-20230004023-A1 | DIFFRACTIVE CONTACT LENSES | ALCON INC. (CH) | 2023-01-05 | — | — | US | claimed |
| WO-2022263994-A1 | MULTIFOCAL DIFFRACTIVE SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2022-12-22 | — | — | WO | claimed |
| US-10011664-B2 | Functionalized nitrile rubbers and the production thereof | ARLANXEO DEUTSCHLAND GMBH (DE) | 2018-07-03 | — | — | US | claimed |
| WO-2026105013-A1 | CONTACT LENSES WITH COLOR FILTERING ZONE | ALCON INC. (CH) | 2026-05-21 | — | — | WO | disclosed |
| US-20260133439-A1 | CONTACT LENSES WITH COLOR FILTERING ZONE | ALCON INC. (CH) | 2026-05-14 | — | — | US | disclosed |
| US-20260118700-A1 | DIFFRACTIVE MULTIFOCAL CONTACT LENS | ALCON INC (CH) | 2026-04-30 | — | — | US | disclosed |
| US-20260104598-A1 | COMPOSITE CONTACT LENSES WITH ULTRATHIN OBJECTS | ALCON INC (CH) | 2026-04-16 | — | — | US | disclosed |
| EP-4719751-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4719753-A1 | METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES | Alcon Inc. (CH) | 2026-04-08 | — | — | EP | disclosed |
| US-5380755-A | Monoamine oxidase inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| US-5101059-A | Xanthene compounds | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| WO-1991008190-A1 | AMINO ACID PROTECTING GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
| EP-0022371-B1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4357332-A | 1-BENZYL-4-/2-HYDROXY-3-BENZYLOXYPROPYL/PIPERAZINES | PFIZER INC. (US) | 1982-11-02 | — | — | US | disclosed |
| EP-0022371-A1 | Substituted piperazines and piperidines and pharmaceutical compositions containing them | PFIZER INC. (US) | 1981-01-14 | — | — | EP | disclosed |
| US-4230599-A | Process for inhibiting foaming utilizing maleic ester copolymer based defoamers, and defoamed compositions | THE DIVERSEY CORPORATION (US) | 1980-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260133439-A1 | CONTACT LENSES WITH COLOR FILTERING ZONE | MYO1G, STRA6, GJA1 | GABRA1 503/4885GABRB2 1443/4885HTR1A 2193/4885 |
| US-20260003210-A1 | DIFFRACTIVE CONTACT LENSES | LBR, CRYZ, CRYAA | GABRA1 473/4885GABRB2 622/4885HTR1A 4572/4885 |
| US-20260104598-A1 | COMPOSITE CONTACT LENSES WITH ULTRATHIN OBJECTS | CRYZ, CRYAA, LIMA1 | GABRA1 718/4885GABRB2 1159/4885HTR1A 3649/4885 |
| US-20260118700-A1 | DIFFRACTIVE MULTIFOCAL CONTACT LENS | DSG1, SDC1, DSP | GABRA1 518/4885GABRB2 1421/4885HTR1A 3527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.